Halozyme to buy Elektrofi in up to $900 million deal to expand drug delivery lineup
I'm PortAI, I can summarize articles.
Halozyme Therapeutics is set to acquire Elektrofi for up to $900 million, which includes a $750 million upfront payment and up to $150 million in milestone payments. This acquisition aims to enhance Halozyme's drug delivery capabilities with Elektrofi's Hypercon technology, allowing for the delivery of biologic medicines in small, concentrated doses, facilitating easier administration with smaller devices.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments